Qide Pharmaceuticals Secures Nearly RMB 100 Million in Pre-B Financing Led by China Renaissance Capital to Advance Global Clinical Development of Next-Generation ADC Drugs

VCBeat has learned that Qide Medical announced the completion of its Pre-B financing round, raising nearly RMB 100 million. The round was led by Huagai Capital, with participation from Huafang Capital and Changjin Boya. Existing Series A investors, Oriza Holdings and TF Capital, continued to increase their investments. The funds raised will be primarily used to advance the global clinical development of next-generation antibody-drug conjugate (ADC) drugs, as well as to accelerate the research, development, and strategic deployment of a series of differentiated innovative technologies and products.

Qide Medical Technology leverages its independently innovated LDC technology and the internationally leading iLDC platform, focusing on the research and development of various types of innovative bioconjugate drugs. The company’s iLDC platform employs an intelligent continuous conjugation process catalyzed by biological enzymes, which has successfully achieved pilot-scale production of next-generation highly homogeneous ADC drugs, significantly improving quality and substantially reducing costs. This platform transforms the existing batch production model of chemical conjugation and can be widely applied to the automated continuous manufacturing of various bioconjugate drugs, represented by ADCs. Based on this platform, Qide Medical Technology has engaged in R&D collaborations with multiple enterprises on diverse types of innovative bioconjugate drugs.

Mr. Zeng Zhiqiang, Managing Partner of Huagai Capital’s Healthcare Fund, stated, “As an internationally leading innovator in ADC drug development based on enzyme-catalyzed conjugation technology, Qide Medical possesses proprietary platform technologies and has the potential to grow into a globally competitive biopharmaceutical leader. We look forward to Qide Medical’s next-generation ADC drugs helping more patients in the future.”

Mr. Zhao Qun, Partner at Oriza Holdings, stated, “We have always been highly optimistic about the application potential of enzyme-catalyzed conjugation technology in the field of ADC drugs. As a company specializing in enzyme-catalyzed conjugation technology, Qide Medical possesses profound technical expertise and innovative reserves. We look forward to the early market launch of Qide Medical’s products to benefit patients.”

Huagai Capital is a private equity investment firm co-founded by professionals from renowned domestic and international investment institutions. With the vision of “becoming a locally rooted asset management firm with global influence,” the company is committed to fostering the growth of Chinese small and medium-sized enterprises into industry leaders. It currently manages multiple equity investment funds, including healthcare, TMT, and cultural industry funds, with assets under management exceeding RMB 10 billion.

Oriza Holdings, a member enterprise of Suzhou Oriza Holdings Co., Ltd., is a professionally managed early-stage equity investment platform operating on market-oriented principles. It focuses primarily on investment opportunities in start-up and growth-stage ventures within the healthcare and TMT sectors. Oriza Holdings has accumulated extensive experience and established strong brand influence in the healthcare sector.

TF Capital focuses on venture capital in the life sciences sector, primarily investing in promising early-stage and growth-stage companies. By leveraging its domain expertise and global industry resources, TF Capital provides comprehensive support to help entrepreneurial partners grow together. Through diversified and strategic investments and by selecting high-quality partners, TF Capital aims to seize opportunities amidst the rapid development of China’s life sciences industry. Since its establishment in 2014, TF Capital has invested in more than 30 emerging life sciences enterprises.

Huafang Capital is a fund specializing in early-stage investments within the biomedical and broader healthcare sector. Adopting a strategy of “industry empowerment” combined with “financial investment,” it focuses on areas such as biopharmaceuticals, high-end medical devices, healthcare services, and healthcare informatics. The management team possesses extensive experience in the healthcare industry and equity investment. Currently, the fund manages approximately RMB 1.6 billion, with its portfolio including numerous high-quality enterprises such as Kelinburui (medical big data), Yichao Medical (ultrasonic surgical medical devices), Aierkang (stem cell new drug R&D), Weilizhibo (new drug R&D), Ruijian Medicine (neural stem cell R&D), and Qide Medicine (new drug R&D).

Changjin Boya is a fund under Chang Development, an industrial ecosystem investment and operation platform wholly established by the Changping District People’s Government of Beijing. Chang Development oversees three major business systems: asset management, technology finance, and industrial services, striving to build a one-stop industrial ecosystem platform that integrates “capital, talent, technology, information, culture, and space.” Currently, Chang Development focuses on areas such as Huilongguan, the Science Park, and Future Science City, having secured nearly 600,000 square meters of equity-based industrial carriers. Its three flagship funds have an initial scale of RMB 2.5 billion, with participating funds totaling RMB 20 billion, and have invested in over 600 projects directly or indirectly.